Lp(a) and risk of cardiovascular disease - A review of existing evidence and emerging concepts

J Natl Med Assoc. 2023 Dec 23:S0027-9684(23)00141-4. doi: 10.1016/j.jnma.2023.11.009. Online ahead of print.ABSTRACTCardiovascular disease (CVD) remains the leading cause of death among adults in the United States. There has been significant advancement in the diagnosis and treatment of atherosclerotic cardiovascular disease (ASCVD) and its underlying risk factors. In certain populations, there remains a significant residual risk despite adequate lowering of low-density lipoprotein cholesterol (LDL-C) and control of traditional risk factors. This has led to an interest in research to identify additional risk factors that contribute to atherosclerotic cardiovascular disease. Elevated lipoprotein (a) [Lp(a)] has been identified as an independent risk factor contributing to an increased risk for CVD. There are also ethnic and racial disparities in Lp(a) inheritance that need to be understood. This paper reviews the current literature on lipoprotein a, proposed mechanisms of actions for cardiovascular disease, recommendations for testing, and the current and emerging therapies for lowering Lp(a).PMID:38143155 | DOI:10.1016/j.jnma.2023.11.009
Source: Journal of the National Medical Association - Category: General Medicine Authors: Source Type: research